AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) has earned an average rating of “Buy” from the seven analysts that are currently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation, five have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $5.50.

A number of brokerages have issued reports on AVEO. BidaskClub raised AVEO Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, July 4th. HC Wainwright began coverage on AVEO Pharmaceuticals in a report on Thursday, August 16th. They set a “buy” rating and a $6.50 price objective for the company.

In related news, major shareholder Equity Opportunities Iv Growth acquired 663,716 shares of the business’s stock in a transaction on Tuesday, August 21st. The stock was bought at an average cost of $2.26 per share, with a total value of $1,499,998.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last three months, insiders have acquired 919,611 shares of company stock valued at $2,002,558. Company insiders own 4.40% of the company’s stock.

Several large investors have recently made changes to their positions in the company. Granahan Investment Management Inc. MA increased its stake in shares of AVEO Pharmaceuticals by 16.3% in the second quarter. Granahan Investment Management Inc. MA now owns 179,512 shares of the biopharmaceutical company’s stock valued at $406,000 after buying an additional 25,134 shares in the last quarter. X Square Capital LLC increased its stake in shares of AVEO Pharmaceuticals by 16.1% in the first quarter. X Square Capital LLC now owns 231,434 shares of the biopharmaceutical company’s stock valued at $671,000 after buying an additional 32,089 shares in the last quarter. Verition Fund Management LLC acquired a new stake in shares of AVEO Pharmaceuticals in the first quarter valued at $122,000. Creative Planning acquired a new stake in shares of AVEO Pharmaceuticals in the second quarter valued at $143,000. Finally, Rhumbline Advisers acquired a new stake in shares of AVEO Pharmaceuticals in the second quarter valued at $209,000. Institutional investors own 50.48% of the company’s stock.

Shares of AVEO stock opened at $2.86 on Friday. The firm has a market capitalization of $340.43 million, a P/E ratio of -17.88 and a beta of 1.62. AVEO Pharmaceuticals has a one year low of $1.86 and a one year high of $4.15. The company has a debt-to-equity ratio of -0.36, a current ratio of 1.16 and a quick ratio of 1.16.

AVEO Pharmaceuticals (NASDAQ:AVEO) last issued its earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.09). The company had revenue of $0.43 million during the quarter, compared to analysts’ expectations of $1.35 million. sell-side analysts predict that AVEO Pharmaceuticals will post -0.26 earnings per share for the current fiscal year.

About AVEO Pharmaceuticals

AVEO Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes a portfolio of targeted medicines for oncology and other areas of unmet medical need. It markets its lead candidate, tivozanib, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC).

Featured Story: Determine Your Level of Risk Tolerance

Receive News & Ratings for AVEO Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.